• Decoy Therapeutics posted a GAAP net loss of $2.37 million for the quarter ended June 30, 2026, widening 148% year over year.
• Revenue rose to $227,629 from no revenue a year earlier, driven solely by a Gates Foundation grant.
• Research and development expense jumped to $1.3 million, up 1,021% year over year, on the post-merger addition of the IMP3ACT program.
• General and administrative costs increased to $1.33 million, up 56% year over year, reflecting inclusion of Legacy Decoy operations.
• Cash, cash equivalents and restricted cash totaled $8.3 million at June 30; $3.5 million gross raised in a June private placement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Decoy Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-346852), on August 12, 2026, and is solely responsible for the information contained therein.